Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ACRS · as of Sep 30, 2025
Ownership Breakdown
103
Institutional Holders
▲ 7 vs Q2
$162.78M
Total Inst. Value
▲ $32.34M vs Q2
120.59M
Shares Outstanding
freeFloat 86.68%
85.68M
13F Shares Held
▼ 6.19M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ACRS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BML CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 14.25M | 11.63% | 11.63% | $27.07B | Nov 10, 2025 | — held |
VIVO CAPITAL, LLC pharmaceutical preparations | 8.89M | 7.25% | 7.25% | $16.89B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 6.52M | 5.32% | 5.32% | $12.38B | Nov 7, 2025 | ▼ 146.6K |
BLACKROCK, INC. pharmaceutical preparations | 5.69M | 4.64% | 4.64% | $10.81B | Nov 12, 2025 | ▲ 176.5K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 5.28M | 4.31% | 4.31% | $10.03B | Nov 14, 2025 | ▼ 4.35M |
ROCK SPRINGS CAPITAL MANAGEMENT LP pharmaceutical preparations | 4.61M | 3.76% | 3.76% | $8.76B | Nov 14, 2025 | ▼ 160.0K |
MORGAN STANLEY pharmaceutical preparations | 4.08M | 3.33% | 3.33% | $7.75B | May 27, 2026 | ▲ 537.1K |
DECHENG CAPITAL LLC pharmaceutical preparations | 4.04M | 3.30% | 3.30% | $7.68B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.39M | 1.95% | 1.95% | $4.54B | Nov 12, 2025 | ▼ 75.2K |
D. E. SHAW & CO., INC. pharmaceutical preparations | 2.37M | 1.94% | 1.94% | $4.51B | Nov 14, 2025 | ▼ 427.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+2.83M shares3
New Positions
first time holders24
Decreased
−10.11M shares0
Sold Out
fully exitedNet shares change (top 50)
7.28M
+2.83M / −10.11M
Net new holders
-3
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ACRS insider trading · insider activity
Source: SEC Form 4
25
Buy transactions
23
Sell transactions
1.09
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
SCHIFF ANDREW N director | Jun 4, 2026 | Award | 42,350 | $4.71 | $199.5K | 42.4K | Form 4 ↗ |
Mehra Anand director | Jun 4, 2026 | Award | 42,350 | $4.71 | $199.5K | 42.4K | Form 4 ↗ |
SCHIFF ANDREW N director | Jun 4, 2026 | Award | 10,987 | — | — | 11.0K | Form 4 ↗ |
Mehra Anand director | Jun 4, 2026 | Award | 10,987 | — | — | 11.0K | Form 4 ↗ |
Molineaux Christopher P. director | Jun 4, 2026 | Award | 42,350 | $4.71 | $199.5K | 42.4K | Form 4 ↗ |
Humphries William D. director | Jun 4, 2026 | Award | 42,350 | $4.71 | $199.5K | 42.4K | Form 4 ↗ |
Humphries William D. director | Jun 4, 2026 | Award | 10,987 | — | — | 11.0K | Form 4 ↗ |
Molineaux Christopher P. director | Jun 4, 2026 | Award | 10,987 | — | — | 11.0K | Form 4 ↗ |
MILANO VINCENT director | Jun 4, 2026 | Award | 42,350 | $4.71 | $199.5K | 42.4K | Form 4 ↗ |
MILANO VINCENT director | Jun 4, 2026 | Award | 10,987 | — | — | 11.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aclaris Therapeutics, Inc. (ACRS) is primarily owned by institutional investors, who hold approximately 71.0% of total shares outstanding. Company insiders own approximately 13.32%, while retail and public investors account for the remaining 15.63%.
The largest institutional shareholder of Aclaris Therapeutics, Inc. is BML CAPITAL MANAGEMENT, LLC, holding approximately 14.25 million shares — equal to 11.63% of outstanding shares — as of September 30, 2025.
A total of 103 institutional investors currently hold ACRS stock, with a combined institutional value of approximately $162,782,120 as of the most recent 13F filing period.
Frequently asked questions
ACRS ownershipAclaris Therapeutics, Inc. (ACRS) is primarily owned by institutional investors, who hold approximately 71.0% of shares. The largest shareholder is BML CAPITAL MANAGEMENT, LLC with a 11.63% stake. Company insiders hold 13.32%. Data sourced from SEC Form 13F as of September 30, 2025.